Cognitive Assessments for Children with Cerebral Palsy Explained
This study looked at how cognitive abilities are assessed in children with cerebral palsy (CP).
This hub covers epilepsy comorbidities, which are the other conditions that often show up alongside seizures (like ADHD, anxiety, depression, autism, and sleep issues). Plain-language research takeaways for families.
Often both. Shared brain networks, stress, sleep disruption, and medication effects can all contribute.
Track timing: New symptoms after med changes or dose increases may point to side effects.
If school is hard, attention/memory changes, or there’s concern about learning, yes, it can guide supports.
Sometimes. Improving sleep and stress can reduce seizure susceptibility in some people.
This study looked at how cognitive abilities are assessed in children with cerebral palsy (CP).
Researchers studied two patients who developed a serious condition called haemophagocytic lymphohistiocytosis (HLH) after starting a medication called lamotrigine, which is often used to treat epilepsy.
Researchers studied a new method for recognizing seizures using electroencephalogram (EEG) data, which measures electrical activity in the brain.
This study looked at epilepsy-dyskinesia syndromes (EDS), which are conditions where people experience both epilepsy and movement disorders.
Researchers examined the effects of levetiracetam, a medication used to treat epilepsy, on mental health, specifically focusing on suicidal thoughts in patients.
Researchers conducted a systematic review and network meta-analysis to compare the effectiveness of various non-drug treatments for anxiety, depression, and quality of life in people with epilepsy.
Researchers conducted a study to evaluate the effectiveness of a medication called fremanezumab in treating patients who experience migraines and also have major depressive disorder.
Researchers conducted a study to understand how effective first-line antiseizure medications (ASMs) are for children newly diagnosed with epilepsy.
Researchers investigated the use of intravenous (i/v) levetiracetam (LEV) as a first-line treatment for patients experiencing non-convulsive status epilepticus (NCSE), a serious condition where seizures occur without noticeable convulsions.